Latest Research

Are you frustrated by the limitations of conventional antibody therapies for B-cell malignancies? CD22—a B-cell specific transmembrane glycoprotein that modulates B-cell receptor (BCR) signaling—is highly expressed on malignant B cells, making it a prime target for immunotherapy. Yet, traditional treatments often suffer from limited receptor engagement and poor tumor penetration. A recent study in Molecular Therapy Oncolytics demonstrates that shark-derived nanobodies may overcome these hurdles.

Can plasma-derived Extracellular Vesicles (EVs) be engineered into precise drug delivery vehicles? Maria Chiara Ciferri and colleagues developed a novel, standardized method to functionalize EV membranes using copper-free click chemistry—eliminating the cytotoxicity issues associated with traditional copper-catalyzed reactions. This advancement not only preserves EV identity but also sets the stage for enhanced therapeutic precision.

What if artificial intelligence could completely revolutionize the way we design nanobody-based therapies for diseases once considered “undruggable”? A recent paper published in Frontiers in Chemistry (source) showcases an innovative AI-driven approach that promises to redefine nanobody development.